• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

    7/18/22 7:00:00 AM ET
    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EDIT alert in real time by email

    CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company's Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the Company's pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology.

    "We are thrilled to have Baisong join our team. He brings to Editas a proven track record of advancing innovative medicines from IND acceptance through global regulatory approval. His extensive drug development experience and deep scientific knowledge make him an ideal partner to our research organization, enabling us to strategically advance our pipeline into and through the clinic," said Gilmore O'Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine. "We are confident Baisong's leadership and expertise will help us achieve our near- and long-term milestones, as we progress our scientific ideas through the drug development process and into commercialized medicines to realize our goal of providing patients with life-changing treatments."

    "Editas Medicine's blend of high-quality science, passion for developing transformative medicines, and urgency for helping patients attracted me to this role, and I am very excited to join the Editas team," said Baisong Mei, M.D., Ph.D., Chief Medical Officer, Editas Medicine. "At Editas, we have the opportunity to make a meaningful difference in patients' lives, as we continue to advance our innovation and development efforts and work toward achieving our goal of bringing multiple transformative medicines to market."

    Dr. Mei brings to Editas more than 20 years of experience in the biotech and pharmaceutical industry, spanning the entire drug development life cycle across multiple disease areas, including hematology, neurology, and other diseases. During his career, Dr. Mei has demonstrated a strong track record in bringing novel medicines through clinical development and global regulatory approval, including Alprolix®, Eloctate®, and Onpattro®. He has led clinical development for multiple new molecular entities (protein, siRNA, gene therapy, and small molecule), from first in human to Phase 3 studies (including pediatric studies) and to regulatory approval in the U.S., EU, Japan, China, and other regions.

    Before working in clinical development, Dr. Mei had a successful career in drug discovery research and CMC development where his leadership and inventions led to the discoveries of one approved drug (Jivi®) and one drug candidate with recent BLA filing (efanesoctocog alfa). Dr. Mei has also led several external strategic partnership collaborations for clinical development and drug discovery.

    Dr. Mei joins Editas Medicine from Sanofi, where he served as Senior Global Project Head in Rare Disease and Rare Blood Disorders. His leadership was critical to the clinical development pipeline in several rare diseases in hematology, neurology, and nephrology. Prior to Sanofi, Dr. Mei was the Therapeutic Area Head for Hematology Clinical Development at Biogen. In this role, he led programs in non-malignant hematology, including hemophilia, sickle cell disease, and beta thalassemia clinical programs. Earlier in his career, Dr. Mei held leadership positions with increasing responsibilities in drug discovery research and CMC development at Biogen and Bayer.

    Dr. Mei earned his Ph.D. from The University of Toledo in Ohio and received his medical education at Bengbu Medical College and Wuhan University School of Medicine in China. Dr. Mei also held postdoctoral fellowships at the University of California San Francisco and the University of California Berkeley. He was a faculty member at the Wuhan University School of Medicine in his early career.

    About Editas Medicine

    As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Harvard and Broad Institute's Cas9 patent estates and Broad Institute's Cas12a patent estate for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

    Forward-Looking Statements

    This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of the Company's product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by Editas Medicine's subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/deebd24c-85e3-4fe6-80bd-11263c6b5974



    Contacts:
    Media
    Cristi Barnett
    (617) 401-0113
    
    [email protected]
    
    Investors
    Ron Moldaver
    (617) 401-9052
    [email protected]

    Primary Logo

    Get the next $EDIT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EDIT

    DatePrice TargetRatingAnalyst
    4/28/2025$3.00Buy
    H.C. Wainwright
    12/16/2024Neutral → Underweight
    Analyst
    12/13/2024Buy → Neutral
    Chardan Capital Markets
    12/13/2024Buy → Hold
    Truist
    12/13/2024$11.00 → $3.00Buy → Hold
    Stifel
    12/11/2024$7.00 → $4.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024$13.00 → $1.00Buy → Underperform
    BofA Securities
    11/6/2024In-line → Outperform
    Evercore ISI
    More analyst ratings

    $EDIT
    Financials

    Live finance-specific insights

    See more
    • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

      On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

      3/5/25 4:05:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

      Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in the liver in non-human primates Ending development of reni-cel after extensive search did not yield a commercial partner The Company will work closely with the clinical trial sites, regulators, and other parties to determine the path forward for patien

      12/12/24 4:00:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Third Quarter 2024 Results and Business Updates

      Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI

      11/4/24 7:30:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Editas Medicine with a new price target

      H.C. Wainwright initiated coverage of Editas Medicine with a rating of Buy and set a new price target of $3.00

      4/28/25 8:37:22 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Analyst

      Analyst downgraded Editas Medicine from Neutral to Underweight

      12/16/24 6:44:11 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Editas Medicine from Buy to Neutral

      12/13/24 8:14:41 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hopfield Jessica bought $253,868 worth of shares (45,000 units at $5.64), increasing direct ownership by 198% to 67,700 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      5/14/24 4:17:23 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/12/24 2:30:25 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/4/24 11:57:08 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      10/17/24 1:10:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Leadership Updates

    Live Leadership Updates

    See more

    $EDIT
    SEC Filings

    See more
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into

      9/25/23 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

      Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

      8/28/23 7:00:57 AM ET
      $EDIT
      $MDNA
      $TNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo

      7/24/23 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Editas Medicine Inc.

      DEFA14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/15/25 4:17:58 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Editas Medicine Inc.

      DEF 14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/15/25 4:16:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Editas Medicine Inc.

      PRE 14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/4/25 4:38:47 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Financial Officer Parison Amy

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:29:42 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Parison Amy claimed ownership of 17,952 shares (SEC Form 3)

      3 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:20:50 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Lucera Erick

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/27/25 4:41:59 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $EDIT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the following upcoming investor conference in May: Bank of America Global Healthcare Conference Format: Fireside ChatDate: Tuesday, May 13Time: 5:15 p.m. PTLocation: Las Vegas, NV To access

      5/5/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to

      4/28/25 4:31:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Chief Financial Officer Transition

      Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer. "We are thrilled to promote Amy to the executive leadership team as our new CFO. Amy joined Editas two and a half years ago as our head of Finance, working closely with the CFO. Her track record of financia

      3/20/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care